GleamWall
中文EN

SMNR Semnur Pharmaceuticals, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1913577 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY87.9%
TTM EPS YoY90.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,344.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,757.8%
Debt / equity—
Current ratio0.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-580.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$2.55M$1.71M
SG&A expense$157.87M$2.98M
Operating income-$160.42M-$4.69M
Interest expense—$96,242
Pretax income$0$0
Income tax$0$0
Net income-$160.42M-$4.69M
EBITDA-$160.42M-$4.69M
EPS (basic)-0.78-0.02
EPS (diluted)-0.78-0.02
Weighted avg. shares (diluted)204.78M200.00M
Banking
Deposits—$75,292
Balance sheet
Cash & equivalents$20,000$12,000
Current assets$596,000$6.00M
PP&E, net$750,000$689,000
Total assets$1.35M$6.68M
Current liabilities$10.17M$35,000
Total liabilities$22.10M$49.47M
Shareholders' equity-$20.75M-$42.78M
Shares outstanding230.21M200.00M
Cash flow statement
Operating cash flow-$5.87M-$4.89M
Investing cash flow—$43.43M
Financing cash flow$5.88M$4.89M
Depreciation & amortization$0$0
Stock-based compensation$142.44M$660,000
Share buybacks—$43.43M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.